■普通感冒是常见的,急性,和轻度上呼吸道疾病。鼻塞被认为是普通感冒中最麻烦的症状,影响生活质量(QoL)。含有类固醇的局部减充血剂对过敏性鼻炎的QoL有益,但是没有发表的研究评估局部减充血剂对普通感冒患者QoL的影响。
■为了评估0.1%盐酸赛洛唑啉的效果(Otrivin,GSK消费者保健SARL,瑞士)与普通感冒相关的鼻塞参与者的QoL长达7天。
■这是一个分散的,纵向,开放标签研究。
■该研究招募了136名具有普通感冒早期症状的参与者(18岁),其中102例纳入改良意向治疗(mITT)人群。收到研究产品后24小时内,参与者确认了一个“鼻子堵塞”和另一个常见的感冒症状。主要终点是威斯康星州上呼吸道症状调查-21(WURSS-21)总分,总体和个体症状评分,和总QoL评分。次要终点是额外的QoL评分。探索性和事后分析包括每个QoL因子的中位天数和五个QoL类别的分析。
■在mITT人群中观察到症状和QoL的一致改善。从第1天开始,“鼻塞”症状有所改善(p=0.0023),WURSS-21总QoL评分,和所有个体QoL评分(全部p<0.0001)。在最后一次需要的剂量之后,睡眠质量显著改善(73%),活力(76%),身体活动(71%),社会活动(80%)和感觉(81%)。没有报告严重或意外的不良事件。
这项研究首次在现实生活中证明,在普通感冒期间使用0.1%盐酸赛洛唑啉治疗成人鼻塞对与日常生活相关的QoL因素有积极影响[Otrivin:现实环境中的生活质量(QoL)影响;https://clinicaltrials.gov/study/NCT05556148]。
0.1%盐酸赛洛唑啉对与普通感冒相关的鼻塞患者生活质量的影响普通感冒是一种普遍存在的疾病,轻微的呼吸道疾病,其标志性症状是鼻塞或鼻塞,这使得呼吸和睡眠变得困难。这项研究的重点是一种名为Otrivin的鼻喷雾剂(含有0.1%的盐酸赛洛唑啉)如何影响因普通感冒而患有鼻充血的人的生活质量(QoL)。参与者回答了一份名为威斯康星州上呼吸道症状调查-21(WURSS-21)的问卷,这有助于了解人们如何经历呼吸道症状以及QoL的不同方面如何受到影响。参与者还回答了WURSS-21中未涵盖的其他八个QoL问题。结果表明,从使用喷鼻剂的第一天起,参与者经历了鼻子阻塞症状的显着缓解,并报告了他们的QoL和幸福感的总体改善,比如睡眠质量,能级,感官,体育和社会活动。总之,这项现实世界的研究表明,在普通感冒期间使用0.1%盐酸赛洛唑啉鼻喷雾剂可以显着改善鼻塞和人日常生活的各个方面。这些发现为使用这种鼻喷雾剂缓解症状和增强普通感冒患者的整体健康提供了有价值的证据。
UNASSIGNED: The common cold is a frequent, acute, and mild upper respiratory human disease. Nasal congestion has been considered the most bothersome symptom in the common cold, impacting quality of life (QoL). Topical decongestants containing steroids benefit QoL in allergic rhinitis, but no published research has assessed the impact of topical decongestants on QoL in the common cold.
UNASSIGNED: To evaluate the effects of xylometazoline hydrochloride 0.1% (Otrivin, GSK Consumer Healthcare SARL, Switzerland) for up to 7 days on QoL in participants with nasal congestion associated with the common cold.
UNASSIGNED: This was a decentralized, longitudinal, open-label
study.
UNASSIGNED: The
study enrolled 136 participants (⩾18 years) with early symptoms of the common cold, of which 102 were included in the modified intention-to-treat (mITT) population. Within 24 h of
study product receipt, participants confirmed a \'plugged nose\' and ⩾1 other common cold symptom. Primary endpoints were Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) total score, total and individual symptom scores, and total QoL score. Secondary endpoints were additional QoL scores. Exploratory and post hoc analyses included median days to resolution for each QoL factor and analyses of five QoL categories.
UNASSIGNED: Consistent improvements in symptoms and QoL were seen in the mITT population. From day 1, improvements were seen in the \'plugged nose\' symptom (p = 0.0023), WURSS-21 total QoL score, and all individual QoL scores (p < 0.0001 for all). After the last dose needed, significant improvements were seen in sleep quality (73%), vitality (76%), physical activity (71%), social activity (80%), and sensation (81%). No serious or unexpected adverse events were reported.
UNASSIGNED: This
study is the first to demonstrate in a real-life setting that treating nasal congestion in adults with xylometazoline hydrochloride 0.1% during the common cold positively impacts QoL factors relevant to daily living [Otrivin: Quality of Life (QoL) Impact in a Real-World Setting; https://clinicaltrials.gov/study/NCT05556148].
Impact of xylometazoline hydrochloride 0.1% on quality of life in people with blocked nose associated with the common coldThe common cold is a widespread, mild respiratory illness for which a hallmark symptom is a blocked or stuffy nose, which makes breathing and sleeping difficult. This
study focused on how a nasal spray called Otrivin (containing xylometazoline hydrochloride 0.1%) impacts the quality of life (QoL) of people suffering from nasal congestion due to the common cold.Participants answered a questionnaire called the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21), which helped understand how people experience respiratory symptoms and how different aspects of QoL were impacted. Participants also responded to eight additional QoL questions not covered in the WURSS-21.The results showed that from the first day of using the nasal spray, participants experienced significant relief from the blocked nose symptom and reported an overall improvement in their QoL and well-being, such as in sleep quality, energy levels, senses, and physical and social activities.In conclusion, this real-world study demonstrated that using xylometazoline hydrochloride 0.1% nasal spray during the common cold can significantly improve nasal congestion and various aspects of a person’s daily life. These findings provide valuable evidence for using this nasal spray to relieve symptoms and enhance the overall well-being of individuals with the common cold.